IP Library › Granted Patent US 9,439,945
Granted Patent B2
US 9,439,945 · App. 14/201,192 · Granted Sep 13, 2016

Isolated nucleotide sequences encoding GDF traps

Inventors: Jasbir Seehra (Lexington, MA); Robert Scott Pearsall (North Reading, MA); Ravindra Kumar (Acton, MA)
Assignee: Acceleron Pharma Inc.
A61K38/1709A61K31/00A61K31/454A61K31/7068A61K38/179A61K38/1796A61K38/1816A61K38/193A61K39/39533C07K14/475C07K14/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,945
App. No.
14/201,192
Granted
Sep 13, 2016
Kind
B2
Abstract

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Claims (15)

1. An isolated nucleic acid comprising a nucleic acid sequence that hybridizes to the complement of nucleotides 76-396 of SEQ ID NO:30 in the presence of 6.0×sodium chloride/sodium citrate (SSC) at 45° C. followed by a wash in 0.2×SSC at 65° C., wherein the nucleic acid sequence encodes a polypeptide that comprises an acidic amino acid at the position corresponding to position 79 of SEQ ID NO:1.

2. The isolated nucleic acid of claim 1 , wherein the nucleic acid hybridizes to the complement of the nucleotide sequence of SEQ ID NO:30 in the presence of 6.0×sodium chloride/sodium citrate (SSC) at 45° C. followed by a wash in 0.2×SSC at 65° C.

3. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises nucleotides 76-396 of SEQ ID NO:30.

4. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO:30.

5. A cultured cell comprising the nucleic acid of claim 1 , wherein the nucleic acid sequence is exogenous.

6. The cultured cell of claim 5 , wherein the cell is a mammalian cell.

7. The cultured cell of claim 6 , wherein the cell is a CHO cell.

8. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises a nucleotide sequence encoding a polypeptide comprising amino acids 26-132 of SEQ ID NO:26.

9. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:26.

10. The isolated nucleic acid of claim 1 , wherein the nucleic acid further comprises a nucleotide sequence encoding a tissue plasminogen activator (TPA) leader sequence.

11. The isolated nucleic acid of claim 1 , wherein the nucleic acid is a recombinant nucleic acid.

12. The isolated nucleic acid of claim 1 , wherein the nucleic acid is operably linked to one or more regulatory sequences.

13. An expression vector comprising the isolated nucleic acid of claim 1 .

14. A cultured cell comprising the expression vector of claim 13 , wherein the cell is a mammalian cell.

15. The cultured cell of claim 14 , wherein the cell is a CHO cell.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2014
From: SEEHRA, JASBIR; PEARSALL, ROBERT SCOTT; KUMAR, RAVINDRA
To: ACCELERON PHARMA INC.
Reel/Frame 033249/0430 →
Continuity (7)
Continuation 13542269 · Jul 5, 2012
Continuation 12856420 · Aug 13, 2010
Continuation In Part PCTUS2009004659 · Aug 13, 2009
Continuation In Part 12583177 · Aug 13, 2009
Provisional Application 61305901 · Feb 18, 2010
Provisional Application 61189094 · Aug 14, 2008
Related Publication 20140314759A1 · Oct 23, 2014